Reviewed by Dr Sarah Mitchell, PhD · Editorial Board
Liraglutide (Saxenda / Victoza) in the UK
Liraglutide was the first long-acting GLP-1 to reach the UK market and still has its place in 2026, particularly where weekly semaglutide or tirzepatide aren't appropriate or available. A patient-pathway view.
What liraglutide is
Liraglutide is a GLP-1 receptor agonist with 97% sequence homology to native human GLP-1, modified to extend the half-life enough for once-daily injection. Two UK-licensed brands, same active ingredient:
- Saxenda — higher-dose, licensed for chronic weight management in eligible adults.
- Victoza — lower-dose, licensed for type 2 diabetes.
Where liraglutide still fits in 2026
Semaglutide and tirzepatide produce greater weight loss on average and require less frequent injection. So why is liraglutide still prescribed?
- Longer real-world safety record — more accumulated years of post-marketing data.
- Daily injection allows finer dose-by-dose control if titration is tricky.
- Sometimes available via NHS pathways or private services where the newer agents are not.
- Cost considerations vary depending on private pricing and supply at any given moment.
UK access — the lawful routes
Same regulated routes as the other GLP-1 medicines: NHS via an eligible weight-management or diabetes service, or private prescription from a UK-registered prescriber, dispensed by a UK-regulated pharmacy. Lawful supply requires a prescription. See our prescription-only medicines page.
Side-effect profile
Similar to semaglutide and tirzepatide:
- Gastrointestinal effects (nausea, vomiting, diarrhoea, constipation) are common at start and during dose escalation.
- Risk of pancreatitis (rare); contraindicated in personal / family history of medullary thyroid carcinoma or MEN2.
- Caution with gallbladder disease and severe gastroparesis.
See side-effect literacy for details across the GLP-1 class.
Questions for your GP or private prescriber
These are starter questions you can adapt for a GP, specialist, pharmacist, or anti-doping advisor. The aim is to help you have a better-informed conversation — not to replace one.
- Why are you proposing liraglutide for me rather than semaglutide or tirzepatide?
- Is a daily injection going to fit my routine?
- What is the dose-titration plan?
- How do you monitor for the rarer side effects (pancreatitis, gallbladder)?
- What is the plan if I want to switch to a weekly agent later?